The effect of small interfering RNA (siRNA) against the Bcl-2 gene on apoptosis and chemosensitivity in a canine mammary gland tumor cell line

被引：15
作者：
Nagamatsu, Kota [1 ]
Tsuchiya, Fumito [1 ]
Oguma, Keisuke [1 ]
Maruyama, Haruhiko [1 ]
Kano, Rui [1 ]
Hasegawa, Atsuhiko [1 ]
机构：
[1] Nihon Univ, Sch Vet Med, Dept Pathol, Kanazawa, Ishikawa 2528510, Japan
来源：
RESEARCH IN VETERINARY SCIENCE | 2008年 / 84卷 / 01期
关键词：
small interfering RNA (siRNA); Bcl-2; canine mammary gland tumor; apoptosis; chemosensitivity; doxorubicin;
D O I：
10.1016/j.rvsc.2007.03.012
中图分类号：
S85 [动物医学（兽医学）];
学科分类号：
0906 ;
摘要：
The aim of this study was to investigate whether downregulation of Bcl-2 expression by small interfering RNA (siRNA) against the canine Bcl-2 gene would enhance the apoptosis and sensitivity of a canine mammary gland tumor cell line (CF33) to doxorubicin. Transfections of CF33 with siRNA were performed using cationic liposomes. Sequence-specific downregulation of Bcl-2 expression was measured by semiquantitative RT-PCR and Western blot analysis. Total viable cells were determined by MTS assay and apoptotic cell rates were determined by the immunohistochemical analysis on ssDNA. Our data showed the siRNA downregulated Bcl-2 expression which increased apotosis and also increased the sensitivity of CF33 to doxorubicin. This study indicated that downregulation of Bcl-2 expression by siRNA would be useful as a new protocol to increase the effect of doxorubicin on treatment of canine mammary gland tumors, requiring a detailed evaluation of siRNA in vivo. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码：49 / 55
页数：7
相关论文
共 48 条
  • [1] The Bcl-2 protein family: Arbiters of cell survival
    Adams, JM
    Cory, S
    [J]. SCIENCE, 1998, 281 (5381) : 1322 - 1326
  • [2] Amundson SA, 2000, CANCER RES, V60, P6101
  • [3] Loss of caveolin-1 polarity impedes endothelial cell polarization and directional movement
    Beardsley, A
    Fang, K
    Mertz, H
    Castranova, V
    Friend, S
    Liu, J
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (05) : 3541 - 3547
  • [4] Mechanisms of anticancer drug resistance
    Bergman, PJ
    [J]. VETERINARY CLINICS OF NORTH AMERICA-SMALL ANIMAL PRACTICE, 2003, 33 (03) : 651 - +
  • [5] BETTAIEB A, 2003, ANTICANC AGENTS, V3, P307
  • [6] BRODEY RS, 1983, J AM ANIM HOSP ASSOC, V19, P61
  • [7] The nuclear transcription factor κB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer
    Buchholz, TA
    Garg, AK
    Chakravarti, N
    Aggarwal, BB
    Esteva, FJ
    Kuerer, HM
    Singletary, SE
    Hortobagyi, GN
    Pusztai, L
    Cristofanilli, M
    Sahin, AA
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (23) : 8398 - 8402
  • [8] Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression
    Chi, KN
    Wallis, AE
    Lee, CH
    de Menezes, DL
    Sartor, J
    Dragowska, WH
    Mayer, LD
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2000, 63 (03) : 199 - 212
  • [9] CLONING AND STRUCTURAL-ANALYSIS OF CDNAS FOR BCL-2 AND A HYBRID BCL-2/IMMUNOGLOBULIN TRANSCRIPT RESULTING FROM THE T(14-18) TRANSLOCATION
    CLEARY, ML
    SMITH, SD
    SKLAR, J
    [J]. CELL, 1986, 47 (01) : 19 - 28
  • [10] Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the β-catenin pathway
    Danilkovitch-Miagkova, A
    Miagkov, A
    Skeel, A
    Nakaigawa, N
    Zbar, B
    Leonard, EJ
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (17) : 5857 - 5868
12345